AU Patent

AU2008275101B2 — Dermal delivery device with in situ seal

Assigned to Agile Therapeutics Inc · Expires 2014-08-21 · 12y expired

What this patent protects

This invention relates to a transdermal drug delivery device that comprises an active ingredient (Al) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the …

USPTO Abstract

This invention relates to a transdermal drug delivery device that comprises an active ingredient (Al) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the Al layer having a peπmeter that extends beyond the perimeter of the Al layer in all directions, and an overlay compπsing a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the Al layer having a peπmeter of which extends beyond the penmeter of the Al layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the peπmeter of the Al layer to form a seal that reduces or prevents volatile component loss.

Drugs covered by this patent

Patent Metadata

Patent number
AU2008275101B2
Jurisdiction
AU
Classification
Expires
2014-08-21
Drug substance claim
No
Drug product claim
No
Assignee
Agile Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.